Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.

Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayser S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL.

J Exp Med. 2012 Jan 16;209(1):35-50. doi: 10.1084/jem.20110540. Epub 2012 Jan 9.

2.

Long-term outcome of treatment with ruxolitinib in myelofibrosis.

Tefferi A, Litzow MR, Pardanani A.

N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555. No abstract available.

3.

JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.

Irino T, Uemura M, Yamane H, Umemura S, Utsumi T, Kakazu N, Shirakawa T, Ito M, Suzuki T, Kinoshita K.

PLoS One. 2011;6(7):e22148. doi: 10.1371/journal.pone.0022148. Epub 2011 Jul 18.

4.

Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.

Xiong H, Du W, Zhang YJ, Hong J, Su WY, Tang JT, Wang YC, Lu R, Fang JY.

Mol Carcinog. 2012 Feb;51(2):174-84. doi: 10.1002/mc.20777. Epub 2011 Apr 22.

PMID:
21520296
5.

Differential biological activity of disease-associated JAK2 mutants.

Zou H, Yan D, Mohi G.

FEBS Lett. 2011 Apr 6;585(7):1007-13. doi: 10.1016/j.febslet.2011.02.032. Epub 2011 Mar 4.

6.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.

J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.

7.

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.

Bixby D, Talpaz M.

Leukemia. 2011 Jan;25(1):7-22. doi: 10.1038/leu.2010.238. Epub 2010 Nov 19. Review.

PMID:
21102425
8.

Networking erythropoiesis.

Kerenyi MA, Orkin SH.

J Exp Med. 2010 Nov 22;207(12):2537-41. doi: 10.1084/jem.20102260. Review.

9.

Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

Wang X, Zhang W, Tripodi J, Lu M, Xu M, Najfeld V, Li Y, Hoffman R.

Blood. 2010 Dec 23;116(26):5972-82. doi: 10.1182/blood-2010-02-269696. Epub 2010 Sep 21.

10.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL.

J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13.

11.

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG.

Blood. 2010 Apr 29;115(17):3589-97. doi: 10.1182/blood-2009-04-215848. Epub 2010 Mar 2.

12.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S.

Blood. 2010 Feb 11;115(6):1131-6. doi: 10.1182/blood-2009-10-246363. Epub 2009 Dec 11.

13.

Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.

Kerr JS, Galloway S, Lagrutta A, Armstrong M, Miller T, Richon VM, Andrews PA.

Int J Toxicol. 2010 Jan-Feb;29(1):3-19. doi: 10.1177/1091581809352111. Epub 2009 Nov 10.

PMID:
19903873
14.

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P, Levine RL, Bhalla KN.

Blood. 2009 Dec 3;114(24):5024-33. doi: 10.1182/blood-2009-05-222133. Epub 2009 Oct 14.

15.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD.

Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8. Review.

16.

Enhanced histone deacetylase enzyme activity in primary myelofibrosis.

Wang JC, Chen C, Dumlao T, Naik S, Chang T, Xiao YY, Sominsky I, Burton J.

Leuk Lymphoma. 2008 Dec;49(12):2321-7. doi: 10.1080/10428190802527699.

PMID:
19052980
17.

Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.

Lee J.

Ann Hematol. 2009 Jul;88(7):699-700. doi: 10.1007/s00277-008-0640-3. Epub 2008 Nov 22. No abstract available.

PMID:
19030859
18.

Myeloproliferative disorders.

Levine RL, Gilliland DG.

Blood. 2008 Sep 15;112(6):2190-8. doi: 10.1182/blood-2008-03-077966. Review.

19.

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.

Grebien F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, Pfeffer K, Klingmüller U, Müller M, Beug H, Müllner EW, Moriggl R.

Blood. 2008 May 1;111(9):4511-22. doi: 10.1182/blood-2007-07-102848. Epub 2008 Jan 31.

20.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.

Items per page

Supplemental Content

Write to the Help Desk